Drugs / JAB-8263
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04587479 | Nov 2020 → Oct 2024 | — | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04686682 | May 2021 → Jan 2028 expected | acute myeloid leukemia, castration-resistant prostate carcinoma, esophageal squamous cell carcinoma, non-small cell lung carcinoma +2 | Jacobio Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07684157 | Jul 2026 → Jun 2027 expected | rheumatoid arthritis | Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JAB-8263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04587479 ↗ |
| Action | Inhibit | “JAB-8263 is a small-molecule inhibitor of the highly conserved bromodomain pockets of the bromodomain and extraterminal (BET) proteins.” NCT04587479 ↗ |
| Modality | Small molecule | “JAB-8263 is a small-molecule inhibitor of the highly conserved bromodomain pockets of the bromodomain and extraterminal (BET) proteins.” NCT04587479 ↗ |
| Route | Oral | “Variable dose, orally Q2D with 28 days each cycle” NCT04587479 ↗ |